BioCentury
ARTICLE | Company News

EC approves Actelion's Uptravi

May 18, 2016 12:31 AM UTC

The European Commission approved Uptravi selexipag from Actelion Ltd. (SIX:ATLN) to treat pulmonary arterial hypertension (PAH). Actelion has rights to the long-acting prostacyclin (IP) receptor ( PGI...